U.S. Hotel and Resort REITs Stock News

NYSE:SE
NYSE:SEMultiline Retail

Sea (SE) Slides Before Earnings, Is It Still 21% Below Fair Value?

Sea (SE) is back in focus after its stock declined 3.4% to close at US$111.00, just days before its August 11 earnings release that will update investors on recent business trends. See our latest analysis for Sea. Following the recent 1-day share price decline of 3.4% to US$111.00, Sea still shows stronger short term momentum with a 90-day share price return of 27.98%. However, the 1-year total shareholder return is down 25.43% and the 5-year total shareholder return is down 63.75%, which...
NYSE:WRBY
NYSE:WRBYSpecialty Retail

Warby Parker (WRBY) Could Be 10% Undervalued Following Profit Return And Guidance Reaffirmation

Warby Parker (WRBY) just posted its second quarter 2026 results, reporting higher revenue, a swing to profit, and reaffirmed full year guidance. The company also highlighted progress in vision care services and the upcoming Intelligent Eyewear product line. See our latest analysis for Warby Parker. Warby Parker shares closed at US$26.96 on 6 August 2026, with the stock falling 7.89% on the day yet still showing a 19.19% year to date share price gain and a very large 3 year total shareholder...
NasdaqGS:ALAB
NasdaqGS:ALABSemiconductor

AI Infrastructure Stocks That Could Benefit Most From Cooling Rate Fears

With Nasdaq futures pointing higher while investors wait for fresh jobs data and inflation clues, attention is swinging back to large technology stocks that often react quickly to shifting rate expectations. This mix of cautious optimism and inflation worries creates an opening for those watching how tech giants are exposed to the latest economic headlines. This article walks through 3 stocks from our Technology Sector Stocks screener that appear positively exposed to the current news. The...
NYSE:DGX
NYSE:DGXHealthcare

The Bull Case For Quest Diagnostics (DGX) Could Change Following Raised Guidance And New Self-Collection Services

In late July 2026, Quest Diagnostics introduced self-collection services for bacterial vaginitis and other common genital tract infections across more than 2,000 patient service centers, alongside publishing large-scale study data on co-infection risks and diagnostic value of modern molecular testing. At the same time, Quest raised its full-year 2026 revenue and earnings guidance after reporting stronger second quarter sales and net income versus the prior year, underscoring how its...
NasdaqGS:XMTR
NasdaqGS:XMTRTrade Distributors

Is Xometry (XMTR) Undervalued After Earnings Growth And Higher 2026 Guidance?

Xometry (XMTR) is back in focus after its 4 August 2026 earnings report, which showed higher quarterly and year to date sales, narrower net losses and an updated outlook for the rest of 2026. See our latest analysis for Xometry. Despite a 1 day share price return of down 5.7% to US$87.09 after the 4 August earnings release, Xometry’s year to date share price return of 38.8% and 1 year total shareholder return of 102.2% suggest momentum has been building over a longer window. The 3 year total...
NasdaqGS:PODD
NasdaqGS:PODDMedical Equipment

Insulet (PODD) Is Down 15.9% After Cutting 2026 Revenue Guidance on Type 2 Retention Strains

In early August 2026, Insulet Corporation reported second-quarter 2026 results showing revenue of US$801.7 million and net income of US$95 million, with basic and diluted EPS of US$1.37, while also trimming full-year 2026 revenue growth guidance to 21%–23% amid softer U.S. Omnipod demand and type 2 retention issues. Beneath the headline beat, management highlighted weaker-than-expected utilization and retention among U.S. type 2 diabetes users and ongoing product quality and litigation...
NYSE:ICE
NYSE:ICECapital Markets

Is Intercontinental Exchange (ICE) Fairly Priced Or Too Expensive Now?

Intercontinental Exchange stock has delivered a 35.4% gain over the past three years, yet the current checks send a mixed message as the Excess Returns intrinsic value estimate points to a roughly fair price while earnings based multiples lean expensive. Over the last three years, Intercontinental Exchange shares are up 35.4%, which puts recent weakness into context after a tougher past year. Planned expansion in fixed income trading and data, including the agreed MarketAxess acquisition and...
NasdaqGM:NTLA
NasdaqGM:NTLABiotechs

Will Phase III lonvo-z Data and Resumed ATTR Program Change Intellia Therapeutics' (NTLA) Narrative

In the past few days, Intellia Therapeutics reported Q2 2026 results showing a net loss of US$106.63 million, or US$0.80 per share, alongside positive Phase III data for its hereditary angioedema gene-editing therapy lonvo-z and a resumed Phase III program in transthyretin amyloidosis after clinical holds were resolved. These updates both highlight the financial strain of Intellia’s R&D-heavy model and mark important clinical milestones that could reshape its future commercialization path in...
NasdaqGS:ICLR
NasdaqGS:ICLRLife Sciences

Should ICON’s Anthropic AI Collaboration Amid Weaker Q2 Profitability Require Action From ICON (ICLR) Investors?

In late July 2026, ICON plc reported second-quarter 2026 results showing slightly higher sales of US$2,063.49 million but materially lower net income of US$72.58 million year-on-year, while reaffirming full-year revenue guidance of US$7.85–US$8.15 billion. ICON plc also announced a multi-year collaboration with Anthropic to embed Claude’s AI across its Orbis platform and clinical trial workflows, highlighting a push to embed advanced AI into protocol design, site selection, and real-time...
NYSE:IFF
NYSE:IFFChemicals

Why International Flavors & Fragrances (IFF) Is Up 6.4% After New $2.5 Billion Buyback And Guidance

International Flavors & Fragrances Inc. recently reported second-quarter 2026 results showing slightly higher sales of US$1,954 million but a sharp drop in net income to US$50 million, alongside updated full-year guidance reflecting discontinued operations. At the same time, the company unveiled a new US$2.50 billion share repurchase program and affirmed its regular quarterly dividend, underscoring management’s capital return priorities during its portfolio reshaping. We’ll now examine how...